Samuel Isaacs


INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2022

NIOX GROUP PLC (formerly Circassia Group plc) (“NIOX” or the “Company” and, together with its subsidiaries, the Group“) Oxford, UK – 14 September 2022: NIOX Group plc (LSE: NIOX), a company engaged in the design, development, and commercialisation of medical devices for asthma

PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2021

Oxford, UK – 22 March 2022: Circassia Group plc (“Circassia” or “the Group”; AIM: CIR), a medical device company focused on point of care asthma diagnosis and management, today announces its audited results for the year ended 31 December 2021.

INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2021

Oxford, UK – 16 September 2021: Circassia Group plc (LSE: CIR), a medical device company focused on point of care asthma diagnosis and management, today announces its unaudited interim results for the six months ended 30 June 2021 (“H1 2021”).

PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2020

Oxford, UK – 24 March 2021: Circassia Group plc (“Circassia” or the “Company” and, together with its subsidiaries, the “Group”) (LSE: CIR) today announces its audited results for the year ended 31 December 2020 and a post-period update. Financial highlights

INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2020

Oxford, UK – 17 September 2020: Circassia Group plc (“Circassia” or “the Company”) (LSE: CIR), a leading medical device business focused on respiratory disease, today announces its unaudited interim results for the six months ended 30 June 2020. Financial highlights

CIRCASSIA GROUP PLC PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2019

Oxford, UK – 16 June 2020: Circassia Group plc (“Circassia” or “the Company”) (LSE: CIR) today announces its preliminary results for the year ended 31 December 2019 and a post-period update. Financial progress Key performance indicators £m 2019 underlying continuing

Proposed transfer of assets to and termination of agreement with AstraZeneca for consideration to be set off against debt and accrued interest

The information contained within this announcement is deemed by Circassia Pharmaceuticals plc to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via a Regulatory Information Service, this inside information